Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | FBP1 | P09467 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123151 | 0.84 | NSD1 (0.51) | ALDH1A1FBP1LMNAMAPTNSD1 | |
| SCHEMBL4139303 | 0.84 | HSD17B10 (0.50) | ALDH1A1FBP1LMNAMAPTNSD1 | |
| SCHEMBL4140328 | 0.83 | FBP1 (0.44) | ALDH1A1FBP1LMNAMAPTCYP3A4 | |
| SCHEMBL4128702 | 0.82 | NPC1 (0.42) | ALDH1A1FBP1LMNAMAPTNSD1 | |
| SCHEMBL4134264 | 0.82 | FBP1 (0.42) | ALDH1A1FBP1LMNAMAPTNSD1 | |
| SCHEMBL4124630 | 0.82 | CYP2C19 (0.41) | ALDH1A1FBP1LMNAMAPTNSD1 | |
| SCHEMBL4134396 | 0.79 | FBP1 (0.42) | ALDH1A1FBP1LMNAGAAPDE10A | |
| SCHEMBL4289343 | 0.78 | TDP1 (0.56) | ALDH1A1FBP1LMNAMAPTCYP3A4 | |
| SCHEMBL4121084 | 0.76 | FBP1 (0.40) | FBP1NSD1GAA | |
| SCHEMBL4133011 | 0.76 | HTT (0.41) | ALDH1A1FBP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | ALDH1A1 852/4885FBP1 1/4885LMNA 3965/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885FBP1 1/4885LMNA 3896/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885FBP1 1/4885LMNA 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.